In a heated legal battle, Alnylam Pharmaceuticals has countered Moderna’s attempt to recover approximately $2.8 million in legal expenses from defending a patent lawsuit concerning its coronavirus vaccine. Alnylam argues that Moderna’s portrayal of the company as “a pernicious patent troll” is unfair and misleading. These accusations arise amidst a broader scrutiny of patent practices in the pharmaceutical sector, particularly as companies strive to protect innovations while avoiding the label often attached to non-practicing entities.
Alnylam’s defense highlights the complex interactions between intellectual property rights and the race for COVID-19 vaccines. This dispute underscores ongoing tensions in balancing proprietary technology rights with public health imperatives. For further details on this legal confrontation, visit the full article on Law360.